Eli Lilly presents positive results from VIVID-2 open-label extension study of Omvoh to treat Crohn's disease at Crohn's and Colitis Congress: Indianapolis Monday, February 10, 20 ...

Eli Lilly (LLY) announced results from the VIVID-2 open-label extension study, which showed the majority of patients with moderately to ...

The findings were based on the VIVID-2 open-label extension study, which is evaluating the e?cacy and safety of Omvoh for up to three years in adults with moderately to severely active Crohn's ...